RE: RNS16 Dec 2024 07:24
More strings :p
1. AWKN-001: an investigational, novel medication-assisted treatment for severe AUD, targeting the UK market, consisting of racemic ketamine (licensed medication in the UK, approved for use as an anaesthetic and as an analgesic, schedule 2 class B) delivered in combination with manualised therapy. Currently, a phase 3 clinical trial is being undertaken in the UK. The phase 2 trial was 100% funded by the UK Medical Research Council (the "MRC"), part of the UK's Department of Health. The phase 3 trial is being co-funded by a partnership between: i) the MRC; ii) the UK National Institute for Health and Care Research ("NIHR"); and iii) Awakn. The phase 3 trial is being managed by the University of Exeter's Clinical Trials Unit and is being run in 9 National Health Trusts in England.
2. AWKN-002: an investigational novel treatment for moderate and severe AUD targeting the US market, consisting of esketamine (a derivative of ketamine, and a licensed medication in UK, approved for the treatment of resistant depression, schedule 2 class B) in an oral thin film plus psycho-social support. A phase 1 trial has been completed with phase 2 trial planning underway.
3. Aminoindane NCE ("new chemical entity") research programme: a pre-clinical programme developing serotonin, dopamine, noradrenalin targeted small molecule therapeutics for trauma related mental health disorders, such as PTSD. Synthesis has been completed by Charnwood Discovery, a provider of drug discovery services, in the UK, and in vitro screening is being conducted by Eurofins Discovery, a leading global provider of drug discovery products and services, in the UK. In vivo testing has been conducted by the University of Nottingham. Initial results from the pre-clinical study of AW21003, a co-lead compound in the aminoindane NCE programme, were announced by Graft Polymer on 11 December 2024.
Sign In
Follow the stocks
